Related Experiment Video
Updated: May 6, 2026

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
Ardeh (Sesamum indicum) could improve serum triglycerides and atherogenic lipid parameters in type 2 diabetic
Parvin Mirmiran1, Zahra Bahadoran, Mahdieh Golzarand
1Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. azizi@endocrine.ac.ir.
Background:
Data suggest that sesame seeds have properties beneficial to modulating lipid disorders and decreasing cardiovascular disease (CVD) risk factors. The aim of this study was to investigate the effects of Ardeh, paste of ground unhulled sesame seeds, on lipid profiles and atherogenic lipid parameters.
Methods:
This randomized clinical trial included 41 patients with type 2 diabetes, who were randomly assigned to one of the two groups: group A (Ardeh 28 g/d, n = 21) and group B (control, n = 20). After an initial two-week washout period, the patients in group A, replaced a part of their usual breakfast with two tablespoon (tbsp) (~ 28 g) Ardeh, while group B patients continued the usual breakfast meal for six weeks; energy content of both breakfast meals was maintained in the same range. Anthropometric measures, blood pressure, serum levels of total cholesterol (TC), triglycerides (TG), LDL-C, HDL-C, and atherogenic index of plasma (AIP; log TG/HDL-C), TC/HDL-C ratio, and LDL/HDL-C ratio were determined at baseline and six weeks later.
Results:
After six weeks, there were significant decreases in serum TG (15.3 mg/dL) and AIP (39 %) in group A. Moreover, slight decreases in serum TC, LDL-C, and other atherogenic lipid parameters and a mild increase in HDL-C also were observed during Ardeh supplementation. Anthropometric measures and blood pressure were unchanged during the study period in both groups.
Conclusion:
Ardeh could have favorable effects in decreasing CVD risk factors in type 2 diabetics.
Related Concept Videos
Atherosclerosis III: Management
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones
